Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 62.58B 9.32B 8.08B 7.62B 6.91B 12.97B 893B 13.07B 91.03B 35.08B 453B 35.01B 34.24B 1,441B P/E 2026 *
47.3x
P/E 2027 * 35.7x
Enterprise Value 57.91B 8.63B 7.47B 7.05B 6.4B 12B 827B 12.09B 84.23B 32.46B 419B 32.4B 31.68B 1,333B EV / Sales 2026 *
7.16x
EV / Sales 2027 * 6.01x
Free-Float
61.13%
Yield 2026 *
0.76%
Yield 2027 * 1.02%
Aug. 25 CIG Shanghai Declares Interim Dividend MT
Aug. 24 CIG Shanghai's H1 Profit More Than Doubles MT
Aug. 24 Asymchem Laboratories' H1 Profit Declines 16% MT
Aug. 24 Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
Jul. 31 Asymchem Laboratories to Subscribe for Subsidiary's New Shares for 1.05 Billion Yuan; Shares Up 6% MT
Jul. 29 Shanghai Asymchem Biotechnology Development Co., Ltd. announced that it expects to receive CNY 1.239699995 billion in funding from Asymchem Laboratories Co., Ltd., Suzhou Gao Ling Qirui Healthcare Investment, L.P. and another investor CI
Jul. 27 AsymBio, Subsidiary of Asymchem Group Kicks Off Construction of Fengxian R&D Building CI
Jul. 10 Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 175.98 Yuan From 132.37 Yuan, Keeps at Buy MT
Jul. 10 Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$131.48 From HK$115.43, Keeps at Buy MT
Jun. 11 Asymchem Laboratories Co., Ltd. Approves Final Profit Distribution Plan to Be Implemented (A Shares) for 2025, Payable on June 26, 2026 CI
May. 27 Asymbio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates CI
May. 20 Citigroup's long position in H shares of Asymchem Laboratories (Tianjin) decreases to 4.99% on May 14 from 5.66%, HKEX filing says RE
May. 15 Asymchem Laboratories Co., Ltd. Recommends Final Dividend for the Year Ended 31 December 2025, Payable on 24 July 2026 CI
Manager TitleAgeSince
Chief Executive Officer 70 1998-10-06
Chief Executive Officer 49 2022-01-18
President - -
Director TitleAgeSince
Director/Board Member 49 2011-07-17
Chairman 70 1998-10-06
Director/Board Member 65 2011-07-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 9.32B
+2.02%-0.96%+50.69%+92.40% 1,015B
+0.28%-3.24%+49.57%+62.65% 642B
+1.81%+2.07%+19.89%+70.38% 463B
-0.84%+2.17%+37.52%+37.02% 353B
0.00%+1.74%+16.47%+23.28% 265B
-0.38%+1.72%+5.83%+10.42% 254B
+1.10%-12.75%+38.03%+45.44% 206B
-0.20%-4.38%-21.37%-58.11% 191B
+1.87%-3.04%+27.81%+89.26% 182B
Average +0.47%-3.35%+24.94%+41.42% 396.69B
Weighted average by Cap. +0.53%-2.21%+33.70%+56.82%

Financials

2026 *2027 *
Net sales 8.09B 1.2B 1.04B 985M 894M 1.68B 115B 1.69B 11.77B 4.53B 58.58B 4.53B 4.43B 186B 9.8B 1.46B 1.27B 1.19B 1.08B 2.03B 140B 2.05B 14.26B 5.49B 71B 5.48B 5.36B 226B
Net income 1.41B 210M 182M 172M 156M 293M 20.15B 295M 2.05B 791M 10.22B 790M 772M 32.5B 1.82B 271M 235M 221M 201M 377M 25.95B 379M 2.64B 1.02B 13.16B 1.02B 994M 41.85B
Net Debt -4.67B -696M -603M -569M -516M -969M -66.72B -976M -6.8B -2.62B -33.85B -2.61B -2.56B -108B -3.66B -545M -472M -445M -404M -758M -52.19B -763M -5.32B -2.05B -26.48B -2.05B -2B -84.18B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!